Prevents pregnancy. ANDA 205069, held by Xiromed. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 205069 (Norethindrone Acetate And Ethinyl Estradiol), held by Xiromed, was first approved by FDA on Jun 22, 2018, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the prevention of pregnancy in women who elect to use combined oral contraceptives as a method of contraception. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the treatment of moderate acne vulgaris in females, ≥ 15 years of age, who have no known contraindications to combined oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 22, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate And Ethinyl Estradiol0.02MG,0.03MG,0.035MG;1MG,1MG,1MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Apr 29, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 18, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 22, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters